[SEN]Theragenbio acquires a patent for infectious disease vaccine development technology such as Corona 19

Genomic data and AI-based, predicting immunity and binding to find optimal antigens

Applicable to hepatitis C and AIDS… Focus on responding to the next new infectious disease

[서울경제TV=배요한기자] Theragenbio announced on March 9 that it has acquired a patent on the immunogen prediction algorithm, a key technology for developing vaccines for novel infectious diseases such as novel coronavirus infection (Corona 19). This patent is’An immunogen prediction method and computer program for virus treatment’.

This is an artificial intelligence (AI) technology that analyzes immunity and binding properties based on viral genome data to predict a sequence region optimized for immunity formation in the body. Predict the binding between the immunogenicity obtained from the virus-derived peptide (amino acid conjugate) sequence and the HLA (Human Leukocyte Antigen) allele sequence that can determine the tissue suitability of the subject, and based on this, it is optimal by inferring the immunity induced after binding. It generates viral antigen information.

In this regard, an official at Theragen Bio said, “With this patented technology, we can design a vaccine model for various viruses.” “We are considering commercialization through the use of our own genome analysis technology and cooperation with domestic and overseas consigned development and production (CDMO) companies. ”Explained. In addition, “this technology can be applied to coronavirus (SARS-CoV-2), MERS, hepatitis C virus, and HIV (AIDS-causing virus), but it is focusing on responding to new infectious diseases that will emerge in the future. “He added.

Theragenbio possesses a viral genome RNA (ribonucleic acid) analysis system using NGS (next-generation sequencing method), and through this patent, it has its own sequencing capability and AI-based infectious disease vaccine development capability at the same time.

The reason why global companies have been able to develop virus vaccines within a short period of time is because they possess both immunogen prediction and production technology at the same time, and in Korea, there are many companies with production capacity, but development has not been speeded up due to lack of immunogen prediction technology.

On the other hand, Theragen Bio was selected as the lead agency for’Advancing Corona 19 Early Diagnosis Technology’, the first national project related to the development of infectious disease quarantine technology, and is currently conducting research. I have progressed.

/Bae Yohan [email protected]

< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >